PRESS RELEASE: Dapagliflozin As Add On Therapy To -2-

26th Jun 2010 19:45

on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business. For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: http://www.astrazeneca-us.com Or call 1-800-AZandMe (292-6363). /CONTACT: Media: Ken Dominski, Bristol-Myers Squibb, +1-609-252-5251, [email protected]; Jim Minnick, AstraZeneca, +1-302-885-5135, [email protected]; Investors: John Elicker, Bristol-Myers Squibb, +1-609-252-4611, [email protected]; Karl Hard, AstraZeneca, +44-20-7304-5322, [email protected]; Clive Morris, AstraZeneca, +44-20-7304-5084, [email protected] Copyright CNW Group 2010 (END) Dow Jones Newswires June 26, 2010 14:45 ET (18:45 GMT)